Literature DB >> 30667276

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.

Guillaume Paré1,2, Artuela Çaku3, Matthew McQueen1,4,5, Sonia S Anand1,6, Enas Enas7, Robert Clarke8, Michael B Boffa9, Marlys Koschinsky10, Xingyu Wang11, Salim Yusuf1.   

Abstract

BACKGROUND: Lipoprotein(a) [Lp(a)] levels predict the risk of myocardial infarction (MI) in populations of European ancestry; however, few data are available for other ethnic groups. Furthermore, differences in isoform size distribution and the associated Lp(a) concentrations have not fully been characterized between ethnic groups.
METHODS: We studied 6086 cases of first MI and 6857 controls from the INTERHEART study that were stratified by ethnicity and adjusted for age and sex. A total of 775 Africans, 4443 Chinese, 1352 Arabs, 1856 Europeans, 1469 Latin Americans, 1829 South Asians, and 1221 Southeast Asians were included in the study. Lp(a) concentration was measured in each participant using an assay that was insensitive to isoform size, with isoform size being assessed by Western blot in a subset of 4219 participants.
RESULTS: Variations in Lp(a) concentrations and isoform size distributions were observed between populations, with Africans having the highest Lp(a) concentration (median=27.2 mg/dL) and smallest isoform size (median=24 kringle IV repeats). Chinese samples had the lowest concentration (median=7.8 mg/dL) and largest isoform sizes (median=28). Overall, high Lp(a) concentrations (>50 mg/dL) were associated with an increased risk of MI (odds ratio, 1.48; 95% CI, 1.32-1.67; P<0.001). The association was independent of established MI risk factors, including diabetes mellitus, smoking, high blood pressure, and apolipoprotein B and A ratio. An inverse association was observed between isoform size and Lp(a) concentration, which was consistent across ethnic groups. Larger isoforms tended to be associated with a lower risk of MI, but this relationship was not present after adjustment for concentration. Consistent with variations in Lp(a) concentration across populations, the population-attributable risk of high Lp(a) for MI varied from 0% in Africans to 9.5% in South Asians.
CONCLUSIONS: Lp(a) concentration and isoform size varied markedly between ethnic groups. Higher Lp(a) concentrations were associated with an increased risk of MI and carried an especially high population burden in South Asians and Latin Americans. Isoform size was inversely associated with Lp(a) concentration, but did not significantly contribute to risk.

Entities:  

Keywords:  apolipoprotein(a); biomarkers; lipoprotein(a); myocardial infarction; risk assessment

Year:  2019        PMID: 30667276     DOI: 10.1161/CIRCULATIONAHA.118.034311

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

1.  Screening for High Lipoprotein(a).

Authors:  George Thanassoulis
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

2.  The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines.

Authors:  Anandita Agarwala; Jing Liu; Christie M Ballantyne; Salim S Virani
Journal:  Curr Cardiovasc Risk Rep       Date:  2019-05-23

3.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort.

Authors:  Eric J Brandt; Arya Mani; Erica S Spatz; Nihar R Desai; Khurram Nasir
Journal:  J Clin Lipidol       Date:  2020-07-03       Impact factor: 4.766

Review 4.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

Review 5.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

Review 6.  Lipoprotein (a): When to Measure and How to Treat?

Authors:  David Rhainds; Mathieu R Brodeur; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2021-07-08       Impact factor: 5.113

Review 7.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

8.  Lipids in South Asians: Epidemiology and Management.

Authors:  Minhal Makshood; Wendy S Post; Alka M Kanaya
Journal:  Curr Cardiovasc Risk Rep       Date:  2019-07-11

9.  Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.

Authors:  Aniruddh P Patel; Minxian Wang (汪敏先); James P Pirruccello; Patrick T Ellinor; Kenney Ng; Sekar Kathiresan; Amit V Khera
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-29       Impact factor: 8.311

10.  Association of Lipoprotein (a) variants with risk of cardiovascular disease: a Mendelian randomization study.

Authors:  Juan Xia; Chunyue Guo; Kuo Liu; Yunyi Xie; Han Cao; Wenjuan Peng; Yanyan Sun; Xiaohui Liu; Bingxiao Li; Ling Zhang
Journal:  Lipids Health Dis       Date:  2021-06-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.